Login to Your Account

Surviving a 'Nuclear Winter'

As UK Funding Withers, Biotechs Look to Charities

By Nuala Moran

Wednesday, March 4, 2009
LONDON - Astex Therapeutics Ltd. is teaming up with the Multiple Myeloma Research Foundation (MMRF) in an agreement that will see the charity award up to $1 million and provide access to clinicians and patients, to carry out Phase II development of AT7519, a cyclin-dependent kinase inhibitor. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription